Download this assay page in pdf format.
Specimen Type: Please contact PBI for collection instructions
Optimum Volume: 0.5 mL
|4 hours||NA||1 year|
Reporting units: ng/mL
Biological or Clinical Significance:
The terminal complement complex (TCC, SC5b-9) is generated by the assembly of C5b through C9 as a consequence of activation of the complement system by either the classical, lectin, or alternative pathways. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g., the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC. For purposes of this document, we refer to all forms of stable terminal complement complex interchangeably as TCC and SC5b-9, recognizing that other complement regulatory proteins, like clusterin (apolipoprotein J), also form these stable complexes and are detectable in the SC5b-9 Plus assay.
Principle of Test Method:
The SC5b-9 assay is a enzyme immunoassay for the quantification of SC5b-9 complex.
1. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev. 1998; 50:59-87.
2. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res. 2004; 30:73-80.
3. Mollnes TE, Haga HJ, Brun JG, Nielsen EW, Sjöholm A, Sturfeldt G, Mårtensson U. Bergh K, Rekvig OP. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology 1999; 38: 933-940.